Literature DB >> 27498955

Kidney cancer: OCT2 demethylation cracks open oxaliplatin resistance.

Andrea Aguilar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27498955     DOI： 10.1038/nrneph.2016.122

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  1 in total

1.  Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin.

Authors:  Yanqing Liu; Xiaoli Zheng; Qinqin Yu; Hua Wang; Fuqing Tan; Qianying Zhu; Lingmin Yuan; Huidi Jiang; Lushan Yu; Su Zeng
Journal:  Sci Transl Med       Date:  2016-07-20       Impact factor: 17.956
  1 in total
  2 in total

Review 1.  Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy.

Authors:  Tianshu Yang; Yunkai Yang; Yan Wang
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

Review 2.  The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.

Authors:  Jiabei Zhou; Yu Kang; Lu Chen; Hua Wang; Junqing Liu; Su Zeng; Lushan Yu
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.